BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sheikine Y, Pavlick D, Klempner SJ, Trabucco SE, Chung JH, Rosenzweig M, Wang K, Velcheti V, Frampton GM, Peled N, Murray M, Chae YK, Albacker LA, Gay L, Husain H, Suh JH, Millis SZ, Reddy VP, Elvin JA, Hartmaier RJ, Dowlati A, Stephens P, Ross JS, Bivona TG, Miller VA, Ganesan S, Schrock AB, Ou SI, Ali SM. BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precis Oncol 2018;2:PO. [PMID: 32913992 DOI: 10.1200/PO.17.00172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Abdelmaksoud-Dammak R, Ammous-Boukhris N, Saadallah-Kallel A, Charfi S, Khemiri S, Khemakhem R, Kallel N, Ben Kridis-Rejeb W, Sallemi-Boudawara T, Khanfir A, Yangui I, Daoud J, Mokdad-Gargouri R. Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma. Genes (Basel) 2022;13:1499. [PMID: 36011410 DOI: 10.3390/genes13081499] [Reference Citation Analysis]
2 Di Federico A, De Giglio A, Gelsomino F, De Biase D, Giunchi F, Palladini A, Sperandi F, Melotti B, Ardizzoni A. Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. Cancers (Basel) 2022;14:3472. [PMID: 35884534 DOI: 10.3390/cancers14143472] [Reference Citation Analysis]
3 Michelotti A, de Scordilli M, Bertoli E, De Carlo E, Del Conte A, Bearz A. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. Int J Mol Sci 2022;23:6748. [PMID: 35743191 DOI: 10.3390/ijms23126748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chou Y, Lin C, Lee C, Pavlick DC, Su P. Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report. Front Oncol 2022;12:838798. [DOI: 10.3389/fonc.2022.838798] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kazdal D, Hofman V, Christopoulos P, Ilié M, Stenzinger A, Hofman P. Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice and diagnostic implications. Genes Chromosomes Cancer 2022. [PMID: 34997651 DOI: 10.1002/gcc.23022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Testa U, Pelosi E, Castelli G. Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling. Expert Rev Mol Diagn 2021;:1-24. [PMID: 34894979 DOI: 10.1080/14737159.2022.2017774] [Reference Citation Analysis]
7 Peng P, Lv G, Hu J, Wang K, Lv J, Guo G. Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients. Ann Transl Med 2021;9:1321. [PMID: 34532458 DOI: 10.21037/atm-21-3570] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Li B, Qu H, Zhang J, Pan W, Liu M, Yan X, Huang X, He X, Lin D, Liu S, Guan R, Wu Y, Ou Q, Bao H, Xu Y, Wu X, Shao Y, Lin N. Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions. NPJ Precis Oncol 2021;5:81. [PMID: 34508169 DOI: 10.1038/s41698-021-00221-z] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Cheng T, Gu Z, Song D, Liu S, Tong X, Wu X, Lin Z, Hong W. Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. J Cancer 2021;12:644-51. [PMID: 33403024 DOI: 10.7150/jca.49391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. J Thorac Oncol 2020;15:1611-23. [PMID: 32540409 DOI: 10.1016/j.jtho.2020.05.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Mitsudomi T. BRAF Fusion - Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol 2019;14:764-5. [PMID: 31027740 DOI: 10.1016/j.jtho.2019.03.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]